|
NCCBA (NC Chinese Business Association) in junction
with support from CAST-NC and China Center is proud to present:
Pharmaceutical and Biotech Opportunities in China - Revisit
Last year, NCCBA organized a meeting about business opportunities
for outsourcing pharmaceutical and biotech operations in China. It generated
excitement and activities among bio-communities in our area. This year, we
will continue to explore this important topic and engage with broader audience
to discuss and network with interested members.
More and more pharmaceutical companies have applied offshore outsourcing as
one of their "must" strategies to increase overall competitiveness
and efficiency by taking advantage of offshore inexpensive, but highly educated
human resources and the enormous market potential. China is becoming a hot
spot for such outsourcing business. However, many companies face difficulties
and concerns from offshore outsourcing when selecting a partner or a company
in countries in China. These difficulties and concerns include credibility
and trust, protection of IP, variability of different business "norms",
technical expertise and experiences necessary to deliver the best services
in price, quality, and quantity in a timely manner.
For the conference we will invite several experts who have first hand experience
with business and give a presentation about such business opportunities. At
the same time, we will organize a group of panelist for to discuss some of
aspects related to the business development and operations.
Speaker:
• Dr. Ken Chang: Dr. Chang was the founder, the President, CEO and Chairman
of the Board of former Ardent Pharmaceuticals, Inc., Durham, North Carolina.
He has raised approximately $35 million since the inception of Ardent Pharmaceuticals
in 1995. Ardent Pharmaceuticals, Inc. was recently merged with Enhance Biotech,
Inc., a public company. Dr. Chang's new title for the Enhance Biotech, Inc.
is the Chief Scientific Officer and President Asia-Pacific Operations. He currently
holds an Adjunct Professor appointment in the Department of Anesthesiology,
Duke University Medical Center, Durham, North Carolina. He was a Principal
Scientist at former Burroughs Wellcome Co. He is the co-inventor for 10 issued
US patents and 8 pending US patents. Dr. Chang has published approximately
200 papers. He is a co-editor of the book entitled "The Delta Receptor" published
by Marcel Dekker, Inc. in 2004. He is an internationally recognized expert
in receptor pharmacology, biochemistry and molecular biology. He pioneered
in the discovery of delta receptors, delta receptor-selective compounds and
the understanding of physiological functions of the delta receptors. Dr, Chang
and his team have discovered at least five potential drug candidates in various
stages of drug development. The company under Dr. Chang's leadership successfully
filed five Investigational New Drug (IND) applications with FDA approval for
clinical studies. The company has also conducted four (4) Phase 1 clinical
trials for various compounds.
Panelists:
• Dr. Xiaodong Wang: Dr. Wang is the co-founder, the President and CEO
of PharmaAdvance Co. in China. PharmaAdvance is a newly established pharmaceutical
technology service provider focusing on providing services for pharmaceutical
and related companies worldwide in the areas of synthetic, medicinal, and process
chemistry. Dr. Wang has broad management and R&D experiences in US pharmaceutical
industry. He was a team leader and principle scientist at Icagen Inc., a public
traded biopharmaceutical company in RTP, NC and a senior research scientist
at Procter & Gamble Pharmaceuticals. During his twelve years of US pharmaceutical
tenure, he has discovered and helped progress a number of compounds into clinics:
two current phase III compounds, ICA-17043 for the treatment of sickle cell
disease, azimilide for antiarrhythmics; one phase II compound for the treatment
of nasal congestion and migraine pain; one pre-clinical compound for the treatment
of learning and memory disorder, dementia, and attention-deficit/hyperactivity
disorder (AD/HD). He has filed 11 patent applications.
• Dr. Jing Zhou: Dr. Zhou earned his Master and Ph.D. degrees in behavior
science from Vanderbilt University, Nashville, Tennessee, USA in 1995. After
his graduation, he worked as a clinical biostatistician on central nerve system
drug development at GlaxoWellcome in Research Triangle Park, North Carolina.
He has participated in various new drug application projects for FDA review
and approval. He is a co-author of a number of drug development research peer-review
articles in leading clinical research journals in the U.S. He was a senior
technical consultant at Tomorrow Associates for clinical trial statistical
analysis for the pharmaceutical industry. Since 2001, he has developed his
business management career with a number of technology companies. He was a
director of business development for a public company based in Ithaca, New
York and has been a senior executive of BioSignia, Inc., a heath information
technology company based in Research Triangle Park, NC since 2002. He has been
the project leader managing a number of post-marketing clinical trial and sales
projects with a leading pharmaceutical company based in Chicago and other U.S.
health technology companies. Currently, he is in charge of business development
for BioSignia's healthcare subsidiary company in Beijing, China.
• Dr. Xiaodi Guo: Dr. Xiaodi Guo is currently the chief scientific officer
of Huahai US Inc. and responsible for API and generic pharmaceutical product
development, getting approval and marketing to US as well as looking for US
outsourcing opportunities to China. He has more than 20 years pharmaceutical
product development experience. Dr Guo has held various scientific and managerial
positions at leading specialty and generic US pharmaceutical companies for
more than 10 years with growing responsibilities from Sr. Scientist, manager,
to director and VP. He was formerly the VP at Abrika Pharmaceuticals where
he established the company's R&D team and research/manufacturing facility
from scratch and led to one product approval and several difficult to develop
IR and CR product filings. In his career, Dr. Guo was the leading contributor
of many advanced drug delivery technologies and NDA/ANDA CR products marketed
in US, including the most successful ADHD product, Adderall XR. Dr. Guo has
more than 40 publications and is the inventor of more than ten patents. He
is the frequently invited speaker in US and China, including the first US-China
Pharma/Life science opportunity conference at Harvard Club NYC in 2004. Dr.
Guo is also a scientific advisor for Coremed and an adjunct professor at Shanghai
Institute of Pharmaceutical Industry, China. Dr. Guo received a Ph.D. degree
from the University of Texas at Austin, USA.
When: 7:00-9:00 pm, Thursday, May 11, 2006.
We will have half-hour of networking social before (starting 6:30pm) and after
the seminar.
Cost: Free for NCCBA and CAST-NC members/$7 for CED members/$10 for non members
Where: MCNC, MCNC Auditorium
Building #1
3021 Cornwallis Road,
Research Triangle Park, NC 27709-2889
*****************Directions*************************
Map and Directions: http://www.ncidea.org/contact.html
Driving Directions:
1. Directions from Raleigh or locations south or east of RTP.
Take I-40 West, toward Chapel Hill/Durham. Take the Durham Freeway (Route
147) North, the sign reads "Exit #279B, 147 North, Durham." Take
the next exit (to the right) marked "Research Triangle Park, Cornwallis
Road." At the end of the exit, turn right onto Cornwallis Road. Continue
after the first light (entrances to GlaxoSmithKline to both the right and left)for
about 0.2 miles - the sign of the entrance to MCNC is on the right-hand side.
The MCNC auditorium is next to the front entrance of the building.
2. Directions from Durham, Chapel Hill, or locations north or west of RTP:
Take I-85 to the Durham Freeway (Route 147). Take the Durham Freeway (Route
147) South to the Cornwallis Road Exit. At the end of the ramp, make right
turn on to Cornwallis Road. Go through the first light if it was not red (entrances
to GlaxoSmithKline to both the right and left), and continue for about 0.2
miles - the entrance to MCNC is on the right-hand side, just after the yellow "Signal
Ahead" sign. The MCNC auditorium is next to the front entrance of the
building.
*********************About NCCBA**********************
North Carolina Chinese Business Association ( NCCBA: www.nc-cba.org ) is a
premier nonprofit charitable and educational business organization. NCCBA's
mission is to represent, serve, and promote the common interests of our membership
and the North Carolina Chinese business community, particularly in promoting
entrepreneurial and corporate development related to sciences and technologies.
NCCBA will serve as a forum for networking and exchanging, for advancing our
knowledge in creating and sustaining successful businesses, and for encouraging
and facilitating coaching and consultation among our members. NCCBA will also
serve as a major catalyst in bridging the China - North Carolina business relationship.
*****************NCCBA Membership*******************
Per requests, NCCBA will accept membership application on the site before
and after the seminar. We encourage professionals and entrepreneurs to join
this exciting non-profit organization. You will be invited to members-only
networking social events, receptions and seminars among many other benefits.
Please call (919) 345-6294 or (919) 481-3038 if you have any question on membership.
More information about NCCBA is available at http://www.nc-cba.org
| 
